Condition
Aggressive B-Cell Non-Hodgkin Lymphoma
Total Trials
4
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Active Not Recruiting1
Unknown1
Recruiting1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06544265Phase 1Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
NCT05025800Phase 1Active Not RecruitingPrimary
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
NCT07432022Phase 1Not Yet Recruiting
A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
NCT05840289UnknownPrimary
A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma
Showing all 4 trials